Anaptysbio (ANAB)

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses on delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases. Other products include ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; and ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs). Additionally, Imsidolimab is an antibody that inhibits the interleukin-36 receptor, which is in Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. AnaptysBio, Inc. was formerly known as Anaptys Biosciences, Inc. and changed its name in July 2006. The company was incorporated in 2005 and is based in San Diego, California.